Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8088837 | 1.00 | FFAR1 (0.55) | FFAR1HTR2AHTR2CHTR2BSCN3A | |
| SCHEMBL8088925 | 0.94 | HTR2A (0.55) | HTR2AHTR2CHTR2BMTNR1AMTNR1B | |
| SCHEMBL8089150 | 0.94 | HTR2A (0.55) | HTR2AHTR2CHTR2BMTNR1AMTNR1B | |
| SCHEMBL18912573 | 0.89 | FFAR1 (0.45) | FFAR1HTR2AHTR2CHTR2BMTNR1A | |
| SCHEMBL8102619 | 0.88 | MTNR1A (0.48) | FFAR1HTR2AHTR2CHTR2BSCN3A | |
| SCHEMBL8088924 | 0.86 | MTNR1A (0.49) | MTNR1AMTNR1B | |
| SCHEMBL8088922 | 0.86 | MTNR1A (0.49) | MTNR1AMTNR1B | |
| SCHEMBL8088455 | 0.84 | MTNR1A (0.49) | MTNR1AMTNR1B | |
| SCHEMBL8088456 | 0.84 | MTNR1A (0.49) | MTNR1AMTNR1B | |
| SCHEMBL8095719 | 0.84 | HTR2A (0.58) | FFAR1HTR2AHTR2CHTR2BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994518-B2 | Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170152221-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-06-01 | — | — | US | disclosed |
| EP-0747346-B1 | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | BRISTOL MYERS SQUIBB CO (US) | 2000-02-16 | — | — | EP | disclosed |
| EP-0747346-A2 | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152221-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF | CHRNA7, CHRNA10, CHRNA5 | FFAR1 556/4885HTR2A 333/4885HTR2C 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.